Efficacy of trastuzumab beyond progression as second-line chemotherapy for HER2-positive advanced gastric cancer
Gastrointestinal Cancer: Targets and Therapy · 2017
DOI: 10.2147/gictt.s145634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastrointestinal Cancer: Targets and Therapy, 2017. Verfasst von Yasuyoshi Sato und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Sato, Y., Yamashita, H., Yagi, K., Aikou, S., Nishida, M., Takenaka, Y., Nomura, S., & Seto, Y. (2017). Efficacy of trastuzumab beyond progression as second-line chemotherapy for HER2-positive advanced gastric cancer. Gastrointestinal Cancer: Targets and Therapy. https://doi.org/10.2147/gictt.s145634
Vancouver
Sato Y, Yamashita H, Yagi K, Aikou S, Nishida M, Takenaka Y, et al. Efficacy of trastuzumab beyond progression as second-line chemotherapy for HER2-positive advanced gastric cancer. Gastrointestinal Cancer: Targets and Therapy. 2017. doi:10.2147/gictt.s145634
BibTeX
@article{Sato2017,
author = {Sato, Yasuyoshi and Yamashita, Hiroharu and Yagi, Koichi and Aikou, Susumu and Nishida, Masato and Takenaka, Yoshiharu and Nomura, Sachiyo and Seto, Yasuyuki},
title = {Efficacy of trastuzumab beyond progression as second-line chemotherapy for HER2-positive advanced gastric cancer},
journal = {Gastrointestinal Cancer: Targets and Therapy},
year = {2017},
doi = {10.2147/gictt.s145634}
}
EUVIMED